Overview

Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis

Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
Olanzapine-containing regimens for CINV prophylaxis may provide even better protection than aprepitant-containing regimens.
Phase:
Phase 2
Details
Lead Sponsor:
Blokhin's Russian Cancer Research Center
Collaborator:
RUSSCO/RakFond
Treatments:
Antiemetics
Aprepitant
BB 1101
Dexamethasone
Dexamethasone acetate
Fosaprepitant
Olanzapine
Ondansetron